| Heading: |
Coronavirus: Drugs |
| Question ID: |
1785927 |
| UIN: |
39290 |
| House: |
Commons |
| Date tabled: |
2025-03-18 |
| Asking Member ID: |
5284 |
| Asking Member display name: |
David Chadwick
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
David Chadwick
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, whether he has had discussions with NICE on the potential use of PEMGARDA to protect clinically vulnerable people against covid-19 in emergency situations. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-03-26 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
It is critical that medicines used in the United Kingdom are safe and effective and as such, medicines cannot be marketed in the UK without a marketing authorisation. These are granted by the Medicines and Healthcare products Regulatory Agency (MHRA) whic... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |